BIIB
Biogen Inc.
Stock
$222.82−3.06 (−1.35%)Close Oct 1, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.9B | $2.2B | $2.9B | $1.5B | $1.4B | $3.6B | $4.2B | $7.1B | $6.2B | $4.6B | $4.6B | $3.9B | $2.9B | $2.3B | $1.9B | $1.7B | $1.6B | $1.1B | $1.6B | $1.0B |
| Capital expenditures | $182M | $154M | $154M | $277M | $240M | $258M | $425M | $515M | $771M | $867M | $616M | $643M | $288M | $246M | $255M | $208M | $173M | $166M | $276M | $284M |
| Free cash flow | $2.7B | $2.1B | $2.7B | $1.3B | $1.1B | $3.4B | $3.8B | $6.6B | $5.4B | $3.7B | $4.0B | $3.3B | $2.7B | $2.1B | $1.6B | $1.5B | $1.5B | $909M | $1.3B | $735M |
| Stock-based compensation | $296M | $291M | $291M | $264M | $254M | $239M | $198M | $182M | $158M | $128M | $155M | $161M | $155M | $136M | $119M | $113M | $168M | $161M | $146M | $123M |
| Buybacks | — | — | $0 | $0 | $750M | $1.8B | $6.7B | $5.9B | $4.4B | $1.4B | $1.0B | $5.0B | $887M | $400M | $985M | $498M | $2.1B | $751M | $739M | $3.0B |
| Free cash flow margin | 26.9% | 20.7% | 28.1% | 12.9% | 11.2% | 30.8% | 28.3% | 45.7% | 40.3% | 30.0% | 34.7% | 30.4% | 27.4% | 30.3% | 29.5% | 30.1% | 30.8% | 20.8% | 31.4% | 23.2% |